文献速递肿瘤 PET/CT

不可手术III期非小细胞肺癌患者放化疗42 Gy前后FDG PET代谢参数的预后价值

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.
PubMed 文献 · J Nucl Med · 2025-04-01

本研究基于前瞻性多中心II/III期试验中158例不可手术III期非小细胞肺癌患者,评估放化疗前与42 Gy时FDG PET参数变化对6个月和1年RECIST 1.1评价的预后价值。A组(实验组)中42 Gy时PET2有残留代谢者(A+)接受74 Gy放疗 boost,无残留者(A-)及B组接受66 Gy标准放疗。多因素分析显示ΔSUVmax是总生存最重要的预后因素,PET2的SUVmax是无进展生存最重要的预后因素。

要点

  • 42 Gy时FDG PET可用于识别不可手术III期非小细胞肺癌放化疗的良好反应者。
  • PET2的SUVmax与ΔSUVmax为独立预后因素,分别与无进展生存和总生存相关。
  • 两组间所有变量均无显著差异,仅放疗剂量存在显著差异(P < 0.001)。

核心结论

  • 42 Gy时FDG PET可识别不可手术III期非小细胞肺癌放化疗的良好反应者。
  • PET2的SUVmax和ΔSUVmax是独立预后因素。

研究设计与样本

  • 前瞻性多中心II/III期研究,共分析158例不可手术III期非小细胞肺癌患者。
  • 患者随机分为实验组(A组)和标准组(B组);A组中42 Gy时PET2有残留代谢者(A+)接受74 Gy放疗boost,A-及B组接受66 Gy标准放疗。
  • 比较A组与B组,测量FDG PET参数包括SUVmax、SUVmean、SUVpeak、瘦体重归一化峰值SUV、瘦体重归一化平均SUV、总病灶糖酵解、总代谢肿瘤体积(肿瘤及淋巴结)和肿瘤MTV。
  • 所有患者放化疗后6个月和1年采用CT按RECIST 1.1评价,评估无进展生存和总生存。

主要发现

  • 除放疗剂量外(P < 0.001),两组患者人口学特征相似。
  • 所有FDG PET摄取和体积参数测量值均相关,因此仅选择SUVmax变化(ΔSUVmax)和总MTV进行分析。
  • 两组间任何变量均无显著差异。
  • 多因素分析中,ΔSUVmax似乎是总生存最重要的预后因素,PET2的SUVmax似乎是无进展生存最重要的预后因素。

关键数值与推荐

  • A+组接受74 Gy放疗boost,A-组和B组接受66 Gy标准放疗剂量。
  • 放疗剂量在两组间差异显著(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to assess the prognostic value of 18F-FDG PET parameter variation between baseline and 42 Gy (PET2) of radiochemotherapy at 6 mo and 1 y of evaluation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1. Methods: In total, 158 patients in a prospective multicenter phase II/III study were analyzed. Patients were randomized into 2 groups: an experimental arm (group A) and a standard arm (group B). Patients from group A with residual metabolism on PET2 (group A+) at 42 Gy received a radiation boost (74 Gy). Patients without residual uptake on 18F-FDG PET at 42 Gy (group A-) and patients in group B received a standard radiotherapy dose (66 Gy). We compared group A with group B. The 18F-FDG PET parameters SUVmax, SUVmean, SUVpeak, peak SUV normalized on lean body mass, mean SUV normalized on lean body mass, total lesion glycolysis, total metabolic tumor volume (MTV) (tumor and nodes), and tumor MTV were measured. All patients were evaluated with RECIST 1.1 using CT at 6 mo and 1 y after radiochemotherapy. Progression-free survival and overall survival were evaluated. Results: Except for the radiotherapy dose (P < 0.001), patient demographic characteristics were similar between the 2 groups (A vs. B). All 18F-FDG PET uptake and volume parameter measurements were correlated. Therefore, only the change in SUVmax (ΔSUVmax) and total MTV were selected for the analysis. There was no significant difference in any variable between the 2 groups. In the multivariate analysis, ΔSUVmax appeared to be the most important prognostic factor for overall survival, and SUVmax of PET2 appeared to be the most important prognostic factor for progression-free survival. Conclusion: 18F-FDG PET at 42 Gy can be used to identify good responders to radiochemotherapy in patients with inoperable stage III nonsmall cell lung cancer. The SUVmax of PET2 and ΔSUVmax are independent prognostic factors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vera P, Giraud P, Hapdey S, et al. Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer. J Nucl Med. 2025. PMID: 40015915. doi:10.2967/jnumed.124.268499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。